Assessment of equivalence of the original tamsulosin and its generics
- Authors: Zyryanov S.K1, Belousov Y.B1, Kamaev A.V1, Krivoborodov G.G1
-
Affiliations:
- Issue: No 5 (2013)
- Pages: 30-34
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279949
- ID: 279949
Cite item
Open Access
Access granted
Abstract
Generics constitute a significant part of the modern pharmaceutical market. The use of generics in the case of their equivalence to the original drug allows to reduce the burden of health care costs. Often, however, the quality of generics does not match that of the original drug. The results of study suggest that the investigated generics of tamsulosin may not be fully recognized as pharmaceutically equivalent to the original drug.
Keywords
Full Text
About the authors
S. K Zyryanov
Email: belouspharma@mtu-net.ru
Yu. B Belousov
A. V Kamaev
G. G Krivoborodov
References
- Boyle P., Napalkov P. The epidemiology of bening prostate hyperplasia and observations on concomitant hypertension Scand. J. Urol. Nephrol. Suppl. 1995; 168: 7-12.
- AUA Practice Guidelines Committee. AUA guideline on management of bening prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J. Urol. 2003; 170 (2 part 1): 530-547.
- Schwinn D.A., Michelotti G.A. a1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the au-subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 2000; 85 (suppl. 2): 6-11.
- McConell I.D., Roeborn C.G., Bautista O.M. et al. The long-term effect of doxazozine, finasteride, and combination therapy on the clinical progression of bening prostatic hyperplasia. N Engl. J. Med. 2003; 349: 2387-2398.
- Lepor H. Long-term efficacy and safety of terazosin in patients with bening prostatic hyperplasia. Terazosin Research Group. Urology 1995; 45: 406-413.
- Nickel J.C., Sander S., Moon T.D. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to bening prostatic hyperplasia. Int. J. Clin. Pract. 2008; 62, 10: 1547-1559.
- www.grls.rosminzdrav.ru
- Division of Drug Management and Policies. Summary of Counterfeit Drug Database as of April 1999 [unpublished manuscript]. Geneva, Switzerland: World Health Organization; 1999.
- Пушкарь Д.Ю., Белоусов Ю.Б., Раснер П.И., Духанин А.С., Манешина О.А. Исследование степени уроселективности препарата Омник® (тамсулозин) и его генерических аналогов. Consilium medicum, 2009; 7: 3-6.
Supplementary files
